Provocholine logo.
Provochonline
Provochonline Solution Logo

Diagnose Asthma with Confidence

Bronchial challenge testing with Provocholine® is an objective means to help establish a diagnosis of asthma. Provocholine (methacholine chloride) is used in the methacholine challenge test (MCT) to measure airway hyperreactivity, a key clinical feature of respiratory conditions such as asthma.

The methacholine challenge test is widely supported by published clinical practice guidelines; it is performed in adults and children 5 years of age and older when a diagnosis of asthma is suspected and spirometry with pre/post bronchodilator is normal or inconclusive. A negative test result can rule out asthma with a high degree of accuracy, allowing healthcare practitioners to assess alternative diagnoses and avoid unnecessary medications or inappropriate treatments.

INTRODUCING

Provocholine Solution.
COMING SOON
provocholine packaging.

Assess Airway Hyperreactivity:

When asthma is suspected

To rule out conditions with similar symptoms to asthma

To evaluate occupational asthma

Two women, doctor and patient, reviewing paperwork

Assess Airway Hyperreactivity:

When asthma is suspected

To rule out conditions with similar symptoms to asthma

To evaluate occupational asthma

provocholine packaging.

Product Information

Product Insert

Provocholine Powder Prescribing Information

Reimbursement

Provochonline Reimbursement Information

Mixing Instructions

ATS Short Dilution Video

ATS Long Dilution Video

ATS Short Dilution Aid
ATS Long Dilution Aid
WARNING: SEVERE BRONCHOCONSTRICTION Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV1 < 60% predicted or adults with FEV1 < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended. Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapidacting inhaled bronchodilator agent (β-agonist). If baseline spirometry is not performed or is measured inaccurately, the initial FEV1 may be underestimated. In this situation, decreases in FEV1 may not be detected after administration of escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increased risk for excessive bronchoconstriction [See Warnings and Precautions- Section 5 of the Product Monograph].